A Phase 1/1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 436 as Monotherapy and in Combination With Other Therapies in Participants With Microsatellite Instability-high (MSI-H)/Mismatch Repair Deficient (dMMR) Solid Tumors
Latest Information Update: 24 Mar 2026
At a glance
- Drugs AMG 436 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Amgen
Most Recent Events
- 19 Mar 2026 Planned End Date changed from 23 Apr 2032 to 28 Jun 2028.
- 19 Mar 2026 Planned primary completion date changed from 23 Apr 2029 to 28 Jun 2028.
- 19 Mar 2026 Planned initiation date changed from 21 Jan 2026 to 23 Mar 2026.